Class II recall: Baxter Healthcare Corporation: Clindamycin Injection USP in 5% Dextrose, 900 mg/50 mL (18 mg/mL), in GALAXY 50
The FDA has classified a recall of Baxter Healthcare's Clindamycin Injection USP in 5% Dextrose (900 mg/50 mL, NDC 0338-4114-50) supplied in GALAXY 50 mL single-dose containers as a Class II recall. The listed reason is cGMP deviations, according to the recall notice; no further details on the specific deviation or clinical risk are provided in the source text.
Most relevant for: Clinicians and pharmacies administering this Baxter clindamycin IV injection product from the affected lot in hospital or infusion settings.
Read the original at FDA Drug Enforcement ReportsSummary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.
Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.
Specialties
More public health updates
- Long-acting injectable HIV therapy noninferior to oral regimen in Africa trialOct 15, 2026
- Ponatinib-Blinatumomab Beats Imatinib-Chemotherapy in Ph-Positive ALLOct 15, 2026
- Adding dobutamine to norepinephrine cut postoperative AKI in septic shockOct 14, 2026
- Trial halted early after intermittent dialysis linked to higher mortalityOct 14, 2026
- Isoflurane Sedation Does Not Reduce Mortality in Respiratory FailureOct 14, 2026